文献速递血液净化与透析慢性肾脏病

欧洲启动肾脏替代治疗患者共病模式变化:ERA-EDTA登记数据

Changes in co-morbidity pattern in patients starting renal replacement therapy in Europe-data from the ERA-EDTA Registry.
PubMed 文献 · Nephrol Dial Transplant · 2018-01-01

该研究利用ERA-EDTA登记中11个国家/地区登记处2005–2014年≥20岁启动RRT患者数据,分析共病患病率。2014年7578例启动RRT患者中70%至少有一种共病,糖尿病39.0%、缺血性心脏病25.0%、充血性心力衰竭22.3%、外周血管病17.7%、恶性肿瘤16.4%、脑血管病15.5%。2005–2014年糖尿病和恶性肿瘤患病率上升,缺血性心脏病和外周血管病下降。

要点

  • 2014年欧洲启动RRT患者中70%至少有一种共病。
  • 糖尿病是最常见共病,占39.0%。
  • 2005–2014年糖尿病与恶性肿瘤患病率上升,缺血性心脏病与外周血管病下降。

核心结论

  • 欧洲启动RRT患者中超过三分之二至少有一种共病。
  • 近十年启动RRT年龄上升伴随共病模式变化:心血管共病下降,糖尿病和恶性肿瘤上升。

研究设计与样本

  • 基于ERA-EDTA登记中11个国家或地区登记处2005–2014年≥20岁启动RRT患者的数据分析。
  • 2014年共纳入7578例启动RRT患者分析共病患病率。

主要发现

  • 2014年7578例启动RRT患者中70%至少有一种共病。
  • 2014年共病患病率:糖尿病39.0%、缺血性心脏病25.0%、充血性心力衰竭22.3%、外周血管病17.7%、恶性肿瘤16.4%、脑血管病15.5%。
  • 共病患病率在不同国家间差异显著。
  • 共病在男性、老年患者及第91天血液透析患者中比女性、年轻患者及腹膜透析患者更常见。
  • 2005–2014年糖尿病和恶性肿瘤患病率上升,缺血性心脏病和外周血管病患病率下降。

临床怎么用

  • 启动RRT前应系统评估共病,尤其关注糖尿病和恶性肿瘤的增加趋势。
  • 针对老年、男性及血液透析患者应加强共病管理。
  • 需注意不同国家间共病模式差异,因地制宜制定透析前评估策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients starting renal replacement therapy (RRT) for end-stage renal disease often present with one or more co-morbidities. This study explored the prevalence of co-morbidities in patients who started RRT in Europe during the period from 2005 to 2014. METHODS: Using data from patients aged 20 years or older from all 11 national or regional registries providing co-morbidity data to the European Renal Association - European Dialysis and Transplant Association Registry, we examined the prevalence of the following co-morbidities: diabetes mellitus (DM) (primary renal disease and/or co-morbidity), ischaemic heart disease (IHD), congestive heart failure (CHF), peripheral vascular disease (PVD), cerebrovascular disease (CVD) and malignancy. RESULTS: Overall, 70% of 7578 patients who initiated RRT in 2014 presented with at least one co-morbidity: 39.0% presented with DM, 25.0% with IHD, 22.3% with CHF, 17.7% with PVD, 16.4% with malignancy and 15.5% with CVD. These percentages differed substantially between countries. Co-morbidities were more common in men than in women, in older patients than in younger patients, and in patients on haemodialysis at Day 91 when compared with patients on peritoneal dialysis. Between 2005 and 2014 the prevalence of DM and malignancy increased over time, whereas the prevalence of IHD and PVD declined. CONCLUSIONS: More than two-thirds of patients initiating RRT in Europe have at least one co-morbidity. With the rising age at the start of RRT over the last decade, there have been changes in the co-morbidity pattern: the prevalence of cardiovascular co-morbidities decreased, while the prevalence of DM and malignancy increased.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Ceretta ML, Noordzij M, Luxardo R, et al. Changes in co-morbidity pattern in patients starting renal replacement therapy in Europe-data from the ERA-EDTA Registry. Nephrol Dial Transplant. 2018. PMID: 29361126. doi:10.1093/ndt/gfx355

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。